Psoriasis treatment: infection risk with biologics
Newer treatments against psoriasis are targeted and are called „biologics“ as a group. However biologics can be divided into two groups, based on their molecular target. The newer ones target Il-17 and include secukinumab and ustekinumab The « older » ones include etanercept, infliximab and adalimumab (which bind tumor necrosis factor (TNF)) Anti-TNF medication is known to…
Details